Estradiol Patch Year-1 Outcomes: What Real Users Report After 12 Months

What the patch labels recorded

Climara's label pools five trials: 614 postmenopausal women treated for 3 months at 0.025, 0.05 or 0.1 mg per day, plus a 72-woman placebo group in the hot-flush trial [1]. Breast pain rose with dose: 5%, 8% and 29% versus 4% on placebo. Headache was 5%, 18% and 13% versus 10%, and abdominal pain 0%, 11% and 16% versus 8% [1].

The Vivelle-Dot label says no clinical trials were conducted with Vivelle-Dot. It is described as bioequivalent to Vivelle, and its reaction table comes from Vivelle studies, where application-site erythema and irritation occurred in 3.2% or less of patients [6].

What longer trials measured

KEEPS-Cog randomized 211 women to transdermal estradiol 50 mcg/day plus micronized progesterone 200 mg for 12 days a month and 262 to placebo, for up to 4 years. It found no treatment-related cognitive benefit, and transdermal estradiol was similar to placebo on mood [5].

ELITE analyzed 567 women after a mean treatment duration of 57 months. Oral estradiol 1 mg/day did not significantly affect verbal memory, executive function or global cognition; the verbal memory difference was -0.06 (95% CI -0.22 to 0.09) [4]. That trial used oral estradiol, not a patch.

Clot risk in the first year

The first-year signal is clearest for oral estrogen. A 2008 meta-analysis of eight observational studies and nine randomized trials reported, in the observational studies, an odds ratio for a first venous thromboembolism of 4.0 (95% CI 2.9 to 5.7) in the first year of oral use versus 2.1 (1.3 to 3.8) with more than one year of use; the pooled transdermal estimate was 1.2 (0.9 to 1.7) [3].

In ESTHER, a French case-control study, 271 women with a first idiopathic clot were compared with 610 matched controls: adjusted odds ratio 0.9 (0.4 to 2.1) for current transdermal users and 4.2 (1.5 to 11.6) for oral users [2]. Both are observational. The patch labels still carry clot warnings and contraindications [1].

What the labels say about use

The Climara label says to start at 0.025 mg/day applied once weekly to the lower abdomen below the navel or the upper buttock, not on the breasts, and to attempt to taper or discontinue at 3- to 6-month intervals [1]. The Vivelle-Dot label gives a starting dose of 0.0375 mg/day applied twice weekly [6]. The Climara label says swimming, bathing or sauna use has not been studied and may reduce adhesion and estradiol delivery [1].

For a postmenopausal woman with a uterus, the Climara label says to consider adding a progestogen to reduce the risk of endometrial cancer; unopposed estrogen raises that risk [1]. The boxed warning remains on both patch labels [1][6]; FDA requested changes in November 2025 [7] and approved six revised labels in February 2026, none for estradiol patches [8][9].